{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T06:15:42Z","timestamp":1780380942395,"version":"3.54.1"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.blre.2022.101014","type":"journal-article","created":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T08:54:59Z","timestamp":1663404899000},"page":"101014","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?"],"prefix":"10.1016","volume":"58","author":[{"given":"Alessandra","family":"Iurlo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2022.101014_bb0005","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes","volume":"130","author":"Valent","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.blre.2022.101014_bb0010","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1056\/NEJM199805283382206","article-title":"Eosinophilia","volume":"338","author":"Rothenberg","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2022.101014_bb0015","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1365-2141.2006.06038.x","article-title":"Eosinophilia: secondary, clonal and idiopathic","volume":"133","author":"Tefferi","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2022.101014_bb0020","doi-asserted-by":"crossref","first-page":"E257","DOI":"10.1002\/ajh.25906","article-title":"A population-based study of chronic eosinophilic leukemia-not otherwise specified in the United States","volume":"95","author":"Ruan","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2022.101014_bb0025","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jaip.2015.06.009","article-title":"Hematologic malignancies identified in patients with hypereosinophilia and hypereosinophilic syndromes","volume":"3","author":"Jin","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.blre.2022.101014_bb0030","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/ajh.23515","article-title":"Eosinophilia in routine blood samples and the subsequent risk of hematological malignancies and death","volume":"88","author":"Andersen","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2022.101014_bb0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000489341","article-title":"The diagnostic work-up of hypereosinophilia","volume":"86","author":"Wang","year":"2019","journal-title":"Pathobiology"},{"key":"10.1016\/j.blre.2022.101014_bb0040","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.101014_bb0045","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2022.101014_bb0050","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.101014_bb0055","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajh.26352","article-title":"World Health Organization-defined eosinophilic disorders:2022 update on diagnosis, risk stratification and management","volume":"97","author":"Shomali","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2022.101014_bb0060","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1080\/17474086.2019.1677461","article-title":"Hypereosinophilic syndromes in the precision medicine era: clinical, molecular aspects and therapeutic approaches (targeted therapies)","volume":"12","author":"Iurlo","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2022.101014_bb0065","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(02)08505-7","article-title":"Treatment of hypereosinophilic syndrome with imatinib mesilate","volume":"359","author":"Gleich","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2022.101014_bb0070","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0145-2126(02)00046-2","article-title":"Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate","volume":"26","author":"Ault","year":"2002","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2022.101014_bb0075","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.blre.2022.101014_bb0080","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/1744666X.2018.1425142","article-title":"Imatinib for the treatment of hypereosinophilic syndromes","volume":"14","author":"Helbig","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.blre.2022.101014_bb0085","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3390\/ijms22020486","article-title":"Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes","volume":"22","author":"Stella","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2022.101014_bb0090","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2006-10-050054","article-title":"Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia","volume":"109","author":"Jovanovic","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.101014_bb0095","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2003-08-2798","article-title":"Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.101014_bb0100","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3324\/haematol.11420","article-title":"The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRa-positive hypereosinophilic syndrome. Results of a multicenter prospective study","volume":"92","author":"Baccarani","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2022.101014_bb0105","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2141.2008.07294.x","article-title":"Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study","volume":"143","author":"Metzgeroth","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2022.101014_bb0110","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MD.0b013e3182a71eba","article-title":"The spectrum of FIP1L1-PDGFRA-associated chronic eosinophilic leukemia: new insights based on a survey of 44 cases","volume":"92","author":"Legrand","year":"2013","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.blre.2022.101014_bb0115","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2008.07033.x","article-title":"A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA expressing patients","volume":"141","author":"Helbig","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2022.101014_bb0120","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00280-011-1582-3","article-title":"Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFR\u03b1-positive chronic eosinophilic leukaemia","volume":"67","author":"Helbig","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.blre.2022.101014_bb0125","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1038\/leu.2012.162","article-title":"Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome","volume":"26","author":"Pardanani","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2022.101014_bb0130","doi-asserted-by":"crossref","first-page":"33229","DOI":"10.18632\/oncotarget.8906","article-title":"Long-term outcomes of imatinib in patients with FIP1L1\/PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China","volume":"7","author":"Qu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2022.101014_bb0135","first-page":"255","article-title":"Exquisite response to imatinib mesylate in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome: a 12-year experience of the Polish Hypereosinophilic Syndrome Study Group","volume":"130","author":"Helbig","year":"2020","journal-title":"Pol Arch Intern Med"},{"key":"10.1016\/j.blre.2022.101014_bb0140","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1182\/blood-2007-07-100164","article-title":"Relapse following discontinuation of imatinib mesylate therapy for FIP1L1\/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing","volume":"110","author":"Klion","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.101014_bb0145","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3109\/10428194.2015.1065983","article-title":"Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript","volume":"57","author":"Helbig","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2022.101014_bb0150","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/bloodadvances.2019001111","article-title":"Treatment-free remission in FIP1L1-PDGFRA\u2013positive myeloid\/lymphoid neoplasms with eosinophilia after imatinib discontinuation","volume":"4","author":"Metzgeroth","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2022.101014_bb0155","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ajh.25945","article-title":"Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: data from 151 patients","volume":"95","author":"Rohmer","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2022.101014_bb0160","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/leu.2011.181","article-title":"Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation","volume":"26","author":"Metzgeroth","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2022.101014_bb0165","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/onc.2010.476","article-title":"The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro","volume":"30","author":"von Bubnoff","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.blre.2022.101014_bb0170","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1586\/era.09.82","article-title":"Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia","volume":"9","author":"Lierman","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.blre.2022.101014_bb0175","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2022.101014_bb0180","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.101014_bb0185","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/leu.2009.2","article-title":"FIP1L1-PDGFRalpha D842V, a novel pan-resistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib","volume":"23","author":"Lierman","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2022.101014_bb0190","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jaci.2007.11.027","article-title":"Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia","volume":"121","author":"Simon","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.blre.2022.101014_bb0195","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/leu.2015.70","article-title":"F604S exchange in FIP1L1-PDGFRA enhances FIP1L1-PDGFRA protein stability via SHP-2 and SRC: a novel mode of kinase inhibitor resistance","volume":"29","author":"Gorantla","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2022.101014_bb0200","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/sj.leu.2404662","article-title":"Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma","volume":"21","author":"Metzgeroth","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2022.101014_bb0205","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/leu.2013.129","article-title":"Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid\/lymphoid neoplasms with PDGFR rearrangements in blast phase","volume":"27","author":"Metzgeroth","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2022.101014_bb0210","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta","volume":"347","author":"Apperley","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2022.101014_bb0215","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2006-05-024828","article-title":"Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders","volume":"109","author":"David","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.101014_bb0220","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1182\/blood-2014-02-555607","article-title":"Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib","volume":"123","author":"Cheah","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.101014_bb0225","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00277-017-3067-x","article-title":"Imatinib in myeloid\/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase","volume":"96","author":"Jawhar","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2022.101014_bb0230","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/gcc.22287","article-title":"Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia-associated myeloproliferative neoplasms","volume":"54","author":"Naumann","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.blre.2022.101014_bb0235","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.leukres.2008.10.004","article-title":"Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRa mutation status","volume":"33","author":"Jain","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2022.101014_bb0240","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.ejim.2016.02.024","article-title":"Imatinib mesylate for unmutated hypereosinophilic syndromes: does it work?","volume":"32","author":"Helbig","year":"2016","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.blre.2022.101014_bb0245","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/all.12843","article-title":"Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome","volume":"71","author":"Khoury","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.blre.2022.101014_bb0250","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1200\/JCO.2012.48.0665","article-title":"Successful treatment with imatinib in a patient with chronic eosinophilic leukemia not otherwise specified","volume":"32","author":"Iurlo","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2022.101014_bb0255","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.18632\/oncotarget.1941","article-title":"Identification of kit(M541L) somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response","volume":"5","author":"Iurlo","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2022.101014_bb0260","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2002-10-3103","article-title":"Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders","volume":"101","author":"Pardanani","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.101014_bb0265","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood-2003-07-2393","article-title":"Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes","volume":"102","author":"Pitini","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.101014_bb0270","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.blre.2022.101014_bb0275","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.jaci.2016.12.957","article-title":"JAK1 gain-of-function causes an autosomal dominant immune dysregulatory and hypereosinophilic syndrome","volume":"139","author":"Del Bel","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.blre.2022.101014_bb0280","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1182\/blood-2012-06-433821","article-title":"Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)\/PCM1-JAK2-positive chronic eosinophilic leukemia","volume":"120","author":"Lierman","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.101014_bb0285","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00277-014-2221-y","article-title":"Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes","volume":"94","author":"Schwaab","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2022.101014_bb0290","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00277-015-2451-7","article-title":"Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene","volume":"94","author":"Rumi","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2022.101014_bb0295","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1200\/JCO.2012.46.4370","article-title":"Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene","volume":"31","author":"Rumi","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2022.101014_bb0300","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jid.2016.10.044","article-title":"Treatment of hypereosinophilic syndrome with cutaneous involvement with the JAK inhibitors tofacitinib and ruxolitinib","volume":"137","author":"King","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.blre.2022.101014_bb0305","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ajh.25825","article-title":"Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes","volume":"95","author":"Schwaab","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2022.101014_bb0310","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1182\/bloodadvances.2020004174","article-title":"Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance","volume":"5","author":"Chen","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2022.101014_bb0315","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3324\/haematol.2012.066407","article-title":"Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome","volume":"98","author":"Chase","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2022.101014_bb0320","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/leu.2012.188","article-title":"Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities","volume":"27","author":"Ren","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2022.101014_bb0325","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/blood.V126.23.2812.2812","article-title":"Limited efficacy of ponatinib in myeloproliferative neoplasms associated with FGFR1 fusion genes","volume":"126","author":"Kreil","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.101014_bb0330","doi-asserted-by":"crossref","first-page":"14479","DOI":"10.1073\/pnas.0404438101","article-title":"PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder","volume":"101","author":"Chen","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2022.101014_bb0335","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1080\/10428194.2017.1397663","article-title":"Myeloid\/lymphoid neoplasms with FGFR1 rearrangement","volume":"59","author":"Strati","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2022.101014_bb0340","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1182\/bloodadvances.2020002308","article-title":"Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia","volume":"4","author":"Kasbekar","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2022.101014_bb0345","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood-2018-99-110388","article-title":"Interim results from Fight-203, a Phase 2, open-label, multicenter study evaluating the efficacy and safety of pemigatinib (INCB054828) in patients with myeloid\/lymphoid neoplasms with rearrangement of fibroblast growth factor receptor (FGFR1)","volume":"132","author":"Verstovsek","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.101014_bb0350","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2011-03-343426","article-title":"Response of ETV6-FLT3-positive myeloid\/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3","volume":"118","author":"Walz","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.101014_bb0355","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1038\/leu.2014.168","article-title":"ETV6-FLT3 fusion gene-positive, eosinophilia- associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant","volume":"28","author":"Falchi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2022.101014_bb0360","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1038\/s41379-021-00817-7","article-title":"Myeloid\/lymphoid neoplasms with FLT3 rearrangement","volume":"34","author":"Tang","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.blre.2022.101014_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106460","article-title":"Myeloid\/lymphoid neoplasms with eosinophilia and FLT3 rearrangement","volume":"99","author":"Shao","year":"2020","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2022.101014_bb0370","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1182\/blood-2005-08-3153","article-title":"The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)\/chronic eosinophilic leukemia (CEL)-like disease","volume":"107","author":"Yamada","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.101014_bb0375","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/all.15056","article-title":"From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases","volume":"77","author":"Pavord","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.blre.2022.101014_bb0380","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jaci.2003.10.049","article-title":"Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes","volume":"113","author":"Garrett","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.blre.2022.101014_bb0385","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1056\/NEJMoa031261","article-title":"Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis","volume":"349","author":"Pl\u00f6tz","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2022.101014_bb0390","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2022.101014_bb0395","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaci.2012.07.055","article-title":"Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes","volume":"131","author":"Roufosse","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.blre.2022.101014_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2010.06.049","article-title":"Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome","volume":"126","author":"Roufosse","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.blre.2022.101014_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2018.04.033","article-title":"Long-term clinical outcomes of high-dose mepolizumab treatment for hypereosinophilic syndrome","volume":"6","author":"Kuang","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.blre.2022.101014_bb0410","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial","volume":"146","author":"Roufosse","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.blre.2022.101014_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2021.07.050","article-title":"Safety and efficacy of mepolizumab in hypereosinophilic syndrome: an open-label extension study","volume":"9","author":"Gleich","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.blre.2022.101014_bb0420","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.jaip.2022.04.037","article-title":"Mepolizumab reduces hypereosinophilic syndrome flares irrespective of blood eosinophil count and interleukin-5","volume":"10","author":"Rothenberg","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.blre.2022.101014_bb0425","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.840974","article-title":"Association between baseline therapy and flare reduction in mepolizumab-treated patients with hypereosinophilic syndrome","volume":"13","author":"Reiter","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2022.101014_bb0430","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1182\/blood-2003-10-3620","article-title":"Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.101014_bb0435","doi-asserted-by":"crossref","first-page":"241","DOI":"10.18176\/jiaci.0366","article-title":"Successful treatment of corticosteroid-refractory hypereosinophilia with reslizumab","volume":"29","author":"Coffey","year":"2019","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.blre.2022.101014_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.blre.2022.101014_bb0445","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2022.101014_bb0450","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2022.101014_bb0455","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2022.101014_bb0460","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-negative hypereosinophilic syndrome","volume":"380","author":"Kuang","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2022.101014_bb0465","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.rmed.2009.09.011","article-title":"Effect of omalizumab on peripheral blood eosinophilia in allergic asthma","volume":"104","author":"Massanari","year":"2010","journal-title":"Respir Med"},{"key":"10.1016\/j.blre.2022.101014_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2013.02.032","article-title":"High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects","volume":"132","author":"Busse","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.blre.2022.101014_bb0475","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.blre.2022.101014_bb0480","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1358\/dot.2017.53.9.2693150","article-title":"Dupilumab: human monoclonal antibody against IL-4R\u03b1 for moderate to severe atopic dermatitis","volume":"53","author":"Paton","year":"2017","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.blre.2022.101014_bb0485","doi-asserted-by":"crossref","first-page":"97","DOI":"10.18176\/jiaci.0682","article-title":"Dupilumab: a review of present indications and off-label uses","volume":"32","author":"Mu\u00f1oz-Bellido","year":"2022","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.blre.2022.101014_bb0490","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.alit.2020.01.002","article-title":"Dupilumab: basic aspects and applications to allergic diseases","volume":"69","author":"Matsunaga","year":"2020","journal-title":"Allergol Int"},{"key":"10.1016\/j.blre.2022.101014_bb0495","first-page":"1","article-title":"Elevation of peripheral blood eosinophils during dupilumab treatment for atopic dermatitis is associated with baseline comorbidities and development of facial redness dermatitis and ocular surface disease","author":"Ferrucci","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.blre.2022.101014_bb0500","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1016\/j.jaip.2021.02.042","article-title":"Complications of switching from anti-IL-5 or anti-IL-5R to dupilumab in corticosteroid-dependent severe asthma","volume":"9","author":"Eger","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.blre.2022.101014_bb0505","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1016\/j.jaip.2021.07.049","article-title":"Hypereosinophilia with systemic manifestations under dupilumab and possibility of dual benralizumab and dupilumab therapy in patients with asthma and CRSwNP","volume":"9","author":"Briegel","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.blre.2022.101014_bb0510","doi-asserted-by":"crossref","first-page":"165","DOI":"10.18176\/jiaci.0823","article-title":"Eosinophilia induced by blocking the IL-4\/IL-13 pathway: potential mechanisms and clinical outcomes","volume":"32","author":"Olaguibel","year":"2022","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.blre.2022.101014_bb0515","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2141.2004.05206.x","article-title":"Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report","volume":"127","author":"Pitini","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2022.101014_bb0520","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.jaci.2009.01.069","article-title":"Treatment of FIP1L1\/PDGFRA-negative hypereosinophilic syndrome with alemtuzumab, an anti-CD52 antibody","volume":"123","author":"Wagner","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.blre.2022.101014_bb0525","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.clml.2012.09.018","article-title":"Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody","volume":"13","author":"Strati","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X22000881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X22000881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:31:29Z","timestamp":1759437089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X22000881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":105,"alternative-id":["S0268960X22000881"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2022.101014","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2022.101014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101014"}}